MGP
ITCI

M&G plc’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

M&G plc’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-116,814
Closed -$9.81M – 480
2024
Q4 		$9.81M Sell
116,814
-7,510
-6% -$617K 0.06% 215
2024
Q3 		$9.08M Buy
+124,324
New +$9.34M 0.03% 236

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

M&G plc's ITCI Position: Q1 2025 in Review

M&G plc sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 116,814 shares — an estimated $9.81M sold.

M&G plc first reported a position in ITCI in Q3 2024 and held it in 2 quarters. The position peaked at $9.81M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • M&G plc reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • M&G plc sold 116,814 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $9.81M.
  • M&G plc first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 2 quarters.
  • M&G plc's Intra-Cellular Therapies Inc. position peaked at $9.81M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on M&G plc's 13F filing for Q1 2025, filed 13 May 2025.